A PGC1α-mediated transcriptional axis suppresses melanoma metastasis

Nature

Volumn 537, Issue 7620, 2016, Pages 422-426

  Luo, Chi ^a   Lim, Ji Hong ^a   Lee, Yoonjin ^a,b   Granter, Scott R ^c   Thomas, Ajith ^a   Vazquez, Francisca ^a,d,e   Widlund, Hans R ^c,f   Puigserver, Pere ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 2; INTEGRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TCF4; UNCLASSIFIED DRUG; VEMURAFENIB; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; ID2 PROTEIN, HUMAN; INDOLE DERIVATIVE; PPARGC1A PROTEIN, HUMAN; SULFONAMIDE; TCF4 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; HETEROGENEITY; METABOLISM; PROTEIN; TUMOR;

ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA CELL LINE; MELANOMA METASTASIS; MITOCHONDRIAL BIOGENESIS; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR INVASION; ANIMAL; CELL MOTION; DEFICIENCY; DRUG EFFECTS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; MALE; MELANOMA; METABOLISM; MITOCHONDRION; MOUSE; NEOPLASM METASTASIS; ORGANELLE BIOGENESIS; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INTEGRINS; MALE; MELANOMA; MICE; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ORGANELLE BIOGENESIS; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84988432420     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19347     Document Type: Article

References (37)

1. Chin, L., Garraway, L. A., Fisher, D. E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182 (2006).
2. Gupta, P. B. et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 37, 1047-1054 (2005).
3. Puigserver, P., Spiegelman, B. M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24, 78-90 (2003).
4. Vazquez, F. et al. PGC1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287-301 (2013).
5. Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1 and MITF. Cancer Cell 23, 302-315 (2013).
6. Plantefaber, L. C., Hynes, R. O. Changes in integrin receptors on oncogenically transformed cells. Cell 56, 281-290 (1989).
7. Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteomics 11, M111 014647-1-18 (2012).
8. Nguyen, D. X., Bos, P. D., Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
9. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
10. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
11. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
12. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003).
13. Hoek, K. S. et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656 (2008).
14. Pinon, P., Wehrle-Haller, B. Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigment Cell Melanoma Res. 24, 282-294 (2011).
15. Busse, A., Keilholz, U. Role of TGF-in melanoma. Curr. Pharm. Biotechnol. 12, 2165-2175 (2011).
16. Damsky, W. E. et al.-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20, 741-754 (2011).
17. Foley, C. J. et al. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J. Biol. Chem. 287, 24330-24338 (2012).
18. Parsons, J. T. Focal adhesion kinase: the first ten years. J. Cell Sci. 116, 1409-1416 (2003).
19. Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., Tavazoie, S. F. Broadspectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156, 986-1001 (2014).
20. Lim, J. H., Luo, C., Vazquez, F., Puigserver, P. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res. 74, 3535-3545 (2014).
21. Langlands, K., Yin, X., Anand, G., Prochownik, E. V. Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. J. Biol. Chem. 272, 19785-19793 (1997).
22. Norton, J. D. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell Sci. 113, 3897-3905 (2000).
23. Zebedee, Z., Hara, E. Id proteins in cell cycle control and cellular senescence. Oncogene 20, 8317-8325 (2001).
24. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res. 41, D816-823 (2013).
25. Franceschini, A. et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-815 (2013).
26. Luo, C. et al. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC. Cancer Res. 73, 4337-4348 (2013).
27. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
28. Sanchez-Laorden, B. et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 7, ra30 (2014).
29. Torrano, V. et al. The metabolic co-regulator PGC1 suppresses prostate cancer metastasis. Nat. Cell Biol. 18, 645-656 (2016).
30. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
31. Talantov, D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11, 7234-7242 (2005).
32. Scatolini, M. et al. Altered molecular pathways in melanocytic lesions. Int. J. Cancer 126, 1869-1881 (2010).
33. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
34. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
35. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
36. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
37. Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. U. S. A. 108, 3665-3670 (2011).